Leerink Partnrs Boosts Earnings Estimates for Insulet

Insulet Co. (NASDAQ:PODD) – Investment analysts at Leerink Partnrs raised their FY2028 earnings per share estimates for shares of Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will earn $7.80 per share for the year, up from their prior estimate of $7.75. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share.

Several other analysts have also issued reports on the stock. Canaccord Genuity Group increased their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Morgan Stanley upped their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Citigroup boosted their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Trading Down 0.1 %

PODD opened at $266.42 on Wednesday. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of 45.62, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a twelve month low of $160.19 and a twelve month high of $279.40. The company has a 50-day simple moving average of $241.97 and a 200 day simple moving average of $211.65.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Baillie Gifford & Co. increased its stake in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after buying an additional 389,639 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares during the period. American Century Companies Inc. lifted its stake in shares of Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after buying an additional 139,246 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its holdings in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.